IRLAB Therapeutics AB (publ) (IRLAB-A) - Net Assets

Latest as of September 2025: Skr54.21 Million SEK ≈ $5.83 Million USD

Based on the latest financial reports, IRLAB Therapeutics AB (publ) (IRLAB-A) has net assets worth Skr54.21 Million SEK (≈ $5.83 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr170.55 Million ≈ $18.35 Million USD) and total liabilities (Skr116.34 Million ≈ $12.52 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IRLAB-A cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr54.21 Million
% of Total Assets	31.79%
Annual Growth Rate	2.46%
5-Year Change	-90.62%
10-Year Change	-64.54%
Growth Volatility	84.93

IRLAB Therapeutics AB (publ) - Net Assets Trend (2013–2024)

This chart illustrates how IRLAB Therapeutics AB (publ)'s net assets have evolved over time, based on quarterly financial data. Also explore IRLAB-A current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for IRLAB Therapeutics AB (publ) (2013–2024)

The table below shows the annual net assets of IRLAB Therapeutics AB (publ) from 2013 to 2024. For live valuation and market cap data, see how much is IRLAB Therapeutics AB (publ) worth.

Year	Net Assets	Change
2024-12-31	Skr32.63 Million ≈ $3.51 Million	-71.81%
2023-12-31	Skr115.76 Million ≈ $12.46 Million	-60.20%
2022-12-31	Skr290.83 Million ≈ $31.30 Million	-27.20%
2021-12-31	Skr399.48 Million ≈ $42.99 Million	+14.83%
2020-12-31	Skr347.88 Million ≈ $37.44 Million	+91.32%
2019-12-31	Skr181.83 Million ≈ $19.57 Million	-14.42%
2018-12-31	Skr212.48 Million ≈ $22.87 Million	+37.08%
2017-12-31	Skr155.00 Million ≈ $16.68 Million	+49.20%
2016-12-31	Skr103.89 Million ≈ $11.18 Million	+12.89%
2015-12-31	Skr92.03 Million ≈ $9.90 Million	+3.90%
2014-12-31	Skr88.57 Million ≈ $9.53 Million	+254.41%
2013-12-31	Skr24.99 Million ≈ $2.69 Million	--

Equity Component Analysis

This analysis shows how different components contribute to IRLAB Therapeutics AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 65860000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	Skr1.04 Million	3.18%
Other Comprehensive Income	Skr1.00K	0.00%
Other Components	Skr690.20 Million	2114.98%
Total Equity	Skr32.63 Million	100.00%

IRLAB Therapeutics AB (publ) Competitors by Market Cap

The table below lists competitors of IRLAB Therapeutics AB (publ) ranked by their market capitalization.

Company	Market Cap
Pearl Gold AG F:02P	$12.86 Million
Hindcon Chemicals Limited NSE:HINDCON	$12.86 Million
Bionano Genomics Inc NASDAQ:BNGO	$12.87 Million
Emova Group SA PA:ALEMV	$12.88 Million
Maxeon Solar Technologies Ltd NASDAQ:MAXN	$12.86 Million
Skin Elements Ltd AU:SKN	$12.84 Million
Pan Malaysia Corporation Bhd KLSE:4081	$12.83 Million
Platinex Inc F:9PX	$12.83 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in IRLAB Therapeutics AB (publ)'s equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 115,764,000 to 32,634,000, a change of -83,130,000 (-71.8%).
Net loss of 83,129,000 reduced equity.
Other comprehensive income increased equity by 1,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	Skr-83.13 Million	-254.73%
Other Comprehensive Income	Skr1.00K	+0.0%
Other Changes	Skr-2.00K	-0.01%
Total Change	Skr-	-71.81%

Book Value vs Market Value Analysis

This analysis compares IRLAB Therapeutics AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.24x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 0.68x to 2.24x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2014-12-31	Skr2.07	Skr1.41	x
2015-12-31	Skr3.77	Skr1.41	x
2016-12-31	Skr4.03	Skr1.41	x
2017-12-31	Skr4.51	Skr1.41	x
2018-12-31	Skr5.46	Skr1.41	x
2019-12-31	Skr4.40	Skr1.41	x
2020-12-31	Skr7.30	Skr1.41	x
2021-12-31	Skr7.72	Skr1.41	x
2022-12-31	Skr5.61	Skr1.41	x
2023-12-31	Skr2.23	Skr1.41	x
2024-12-31	Skr0.63	Skr1.41	x

Capital Efficiency Dashboard

This dashboard shows how efficiently IRLAB Therapeutics AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -254.73%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -87.85%
• Asset Turnover: 0.69x
• Equity Multiplier: 4.17x
Recent ROE (-254.73%) is below the historical average (-57.55%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	6.17%	5781.48%	0.00x	2.10x	Skr-1.93 Million
2015	-12.92%	-412.74%	0.03x	1.10x	Skr-21.09 Million
2016	-41.10%	-29650.00%	0.00x	1.09x	Skr-53.08 Million
2017	-36.27%	-51582.57%	0.00x	1.05x	Skr-71.72 Million
2018	-34.87%	-411661.11%	0.00x	1.06x	Skr-95.35 Million
2019	-52.97%	-370453.85%	0.00x	1.14x	Skr-114.50 Million
2020	-26.40%	-30616.00%	0.00x	1.06x	Skr-126.64 Million
2021	12.96%	24.92%	0.44x	1.18x	Skr11.83 Million
2022	-39.27%	-186.80%	0.19x	1.11x	Skr-143.29 Million
2023	-153.62%	-3132.07%	0.03x	1.53x	Skr-189.42 Million
2024	-254.73%	-87.85%	0.69x	4.17x	Skr-86.39 Million

Industry Comparison

This section compares IRLAB Therapeutics AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $165,054,194
Average return on equity (ROE) among peers: -81.86%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
IRLAB Therapeutics AB (publ) (IRLAB-A)	Skr54.21 Million	6.17%	2.15x	$12.86 Million
2cureX AB (2CUREX)	$74.34 Million	-25.47%	0.06x	$4.90 Million
Ascelia Pharma AB (publ) (ACE)	$74.33 Million	-147.03%	0.17x	$40.96 Million
AcouSort AB (ACOU)	$15.58 Million	-57.51%	0.12x	$8.97 Million
Active Biotech AB (ACTI)	$188.64 Million	-118.73%	1.64x	$17.19 Million
Alzinova AB (ALZ)	$20.63 Million	-16.51%	0.08x	$4.97 Million
AlzeCure Pharma (ALZCUR)	$182.01 Million	-28.02%	0.03x	$18.18 Million
Annexin Pharmaceuticals AB (ANNX)	$18.81 Million	-234.16%	0.42x	$11.24 Million
Alligator Bioscience AB (ATORX)	$68.52 Million	-112.06%	0.43x	$14.33 Million
BioInvent International AB (BINV)	$219.00 Million	-63.86%	0.22x	$155.44 Million
BioArctic AB (publ) (BIOA-B)	$788.68 Million	-15.19%	0.14x	$2.59 Billion

About IRLAB Therapeutics AB (publ)

ST:IRLAB-A Sweden Biotechnology

Market Cap

$12.86 Million

Skr119.48 Million SEK

Market Cap Rank

#26241 Global

#563 in Sweden

Share Price

Skr1.41

Change (1 day)

-0.85%

52-Week Range

Skr1.41 - Skr7.58

All Time High

Skr104.95